Hussein Ahmed, Awad Mohammad Shafiq, Sabra Ahlam M, Mahmoud Hossam Eldin M
Department of Internal Medicine, Faculty of Medicine, Sohag University, Nasser City, Sohag, 82524, Egypt.
Department of Cardiology, Faculty of Medicine, Beni Suef University, Beni Suef City, 62511, Egypt.
Egypt Heart J. 2021 May 1;73(1):40. doi: 10.1186/s43044-021-00163-8.
Conflicting data were found regarding the anemia's effect on percutaneous coronary intervention (PCI) outcomes. We directed our study to investigate anemia's effect on clinical in-stent restenosis (ISR) following PCI.
A prospective multi-center cohort study was performed on 470 consecutive participants undergoing elective PCI. We classified the participants into two groups: group 1 who were anemic and group 2 who were non-anemic as a control group. At 1, 3, 6, and 12 months by clinic visits, we followed up with the patients to assess anemia's clinical ISR effect. We found that 20% of the patients undergoing PCI had anemia. Anemic patients showed a statistically significant higher rate of impaired renal function and diabetes and a higher percentage of the female gender. Multivariate regression analysis for major adverse cardiovascular events (MACEs) after adjusting for confounding factors revealed that anemia represents a more risk on MACE (adjusted hazard ratio (HR) was 4.13; 95% CI 2.35-7.94; p value < 0.001) and carries a higher risk upon clinical ISR (adjusted HR was 3.51; 95% CI 1.88-7.16; p value < 0.001) over 12 months of follow-up.
Anemic patients going through PCI are generally females, diabetics, and have renal impairment. Anemia might be considered another indicator for clinical ISR and is fundamentally associated with an increased MACE incidence.
关于贫血对经皮冠状动脉介入治疗（PCI）结果的影响，存在相互矛盾的数据。我们开展本研究以调查贫血对PCI术后临床支架内再狭窄（ISR）的影响。
对470例连续接受择期PCI的参与者进行了一项前瞻性多中心队列研究。我们将参与者分为两组：第1组为贫血患者，第2组为非贫血患者作为对照组。通过门诊随访1、3、6和12个月时，我们对患者进行随访以评估贫血对临床ISR的影响。我们发现，接受PCI的患者中有20%患有贫血。贫血患者的肾功能损害和糖尿病发生率在统计学上显著更高，女性比例也更高。在调整混杂因素后对主要不良心血管事件（MACE）进行多变量回归分析显示，贫血对MACE的风险更高（调整后风险比（HR）为4.13；95%置信区间2.35 - 7.94；p值<0.001），并且在12个月的随访中，对临床ISR的风险也更高（调整后HR为3.51；95%置信区间1.88 - 7.16；p值<0.001）。
接受PCI的贫血患者通常为女性、糖尿病患者且有肾功能损害。贫血可能被视为临床ISR的另一个指标，并且与MACE发生率增加有根本关联。
